<DOC>
	<DOCNO>NCT02518802</DOCNO>
	<brief_summary>This randomized phase III trial study gefitinib synchronous pemetrexed/cisplatin chenmotherapy see well work compare pemetrexed/cisplatin chenmotherapy alone treat patient undergone surgery stage II-IIIA ( N1-N2 ) lung adenocarcinoma EGFR activate mutation Asian population .</brief_summary>
	<brief_title>Pemetrexed Combined With Synchronous Gefitinib Adjuvent Therapy Patient With EGFR Mutant Lung Adenocarcinoma</brief_title>
	<detailed_description>Adjuvant cisplatin-based chemotherapy recommend routine use patient stage IIA , IIB , IIIA non-small cell lung cancer ( NSCLC ) complete resection . Cisplatin pemetrexed combination standard regimen lung adenocarcinoma adjuvant setting . The BR . 19 trial report adjuvant gefitinib complete resection early stage NSCLC ( stage IB 49 % , II 38 % , III 13 % ) confer disease free survival ( DFS ) overall survival ( OS ) advantage overall population . While median gefitinib treatment time 4.8 month . There 76 patient EGFR mutation include analysis . The study close prematurely 2005 . Activating somatic mutation tyrosine kinase domain epidermal growth factor receptor ( EGFR ) characterize subset patient advance NSCLC.The EGFR mutation rate 30 % Chinese NSCLC . Patients harbor mutation tumor show excellent response EGFR tyrosine kinase inhibitor ( EGFR-TKIs ) . This randomized phase III trial study gefitinib synchronous pemetrexed/cisplatin chenmotherapy see well work compare pemetrexed/cisplatin chenmotherapy alone treat patient undergone surgery stage II-IIIA ( N1-N2 ) lung adenocarcinoma EGFR activate mutation Asian population .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent provide . Males female age ≥18 year , &lt; 70 year . Able comply require protocol followup procedure , able receive oral medication . Target population completely resect pathological stage IIIIIA ( N1N2 ) NSCLC EGFR exon 19 deletion exon 21 L858R activate mutation . Patient start investigational therapy within 36 week complete resection ECOG performance status 01 . Life expectancy ≥12 week . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥2.0 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN subject without liver metastasis ; ≤ 5 x ULN subject liver metastasis . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , ≥ 60 ml/min . Female subject pregnant breastfeeding . Known severe hypersensitivity gefitinib excipients product . Known severe hypersensitivity premedications require treatment cisplatin / vinorelbine doublet chemotherapy . Inability comply protocol study procedure . A serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability complete study . A serious cardiac condition , myocardial infarction within 6 month , angina , heart disease . Interstitial pneumonia . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . Patients prior chemotherapy therapy systemic antitumour therapy ( e.g . monoclonal antibody therapy ) . Patients prior radiotherapy History another malignancy last 5 year exception following : Other malignancy cure surgery alone continuous diseasefree interval 5 year permit . Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Eye inflammation eye infection fully treat condition predispose subject . Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication . Patient active serious infection ( e.g . pyrexia 38.0℃ ) Patients harbour exon 20 T790M mutation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Gefitinib</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Synchronous therapy</keyword>
	<keyword>Adjuvent therapy</keyword>
</DOC>